Treatment of Patients With Metastatic Pancreatic Cancer With Gemcitabine and Nab-Paclitaxel and Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF)
Barbara Ann Karmanos Cancer Institute
Summary
The goal of this study is to learn if the combination of nab-paclitaxel, gemcitabine and an Amplitude-Modulated Radiofrequency Electromagnetic Fields device (Therabionic P1) is safe and effective for patients with adenocarcinoma of the pancreas.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients must have histologically or cytologically proven advanced metastatic adenocarcinoma of the pancreas. Patients with mixed tumor with predominant adenocarcinoma pathology can be enrolled. * One or more measurable metastatic tumors per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) on imaging studies CT or MRI or PET scans * If female patient is of childbearing potential must have a negative serum pregnancy test (βhCG) documented up to 48 hrs prior to administration of chemotherapy. * Females of childbearing potential and males with female partners of c…
Interventions
- DrugNab paclitaxel
125 mg/m2 weekly, on days 1,8, and 15 or on days 1 and 15 as a 30-40 minute infusion administered first
- DrugGemcitabine
1000 mg/m2 weekly, on day 1,8 and 15 or 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab- paclitaxel infusion
- DeviceTheraBionic P1
This treatment consists of delivering preset low levels of radio waves into the body with a spoon-shaped antenna placed in the mouth, three times a day, for an hour each time.
Locations (7)
- Karmanos Cancer Institute at McLaren ClarkstonClarkston, Michigan
- Karmanos Cancer InstituteDetroit, Michigan
- Karmanos Cancer Institute at McLaren FlintFlint, Michigan
- Karmanos Cancer Institute at McLaren Greater LansingLansing, Michigan
- Karmanos Cancer Institute at McLaren Lapeer RegionLapeer, Michigan
- Karmanos Cancer Institute at McLaren Northern Michigan, PetoskeyPetoskey, Michigan